NEWS HIGHLIGHTSMedia Articles Related to Combivent (Ipratropium / Albuterol)
Chronic Obstructive Pulmonary Disease
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2006.10.13]
Title: Chronic Obstructive Pulmonary Disease
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 10/13/2006
Published Studies Related to Combivent (Ipratropium / Albuterol)
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
BACKGROUND: The pathology of chronic obstructive pulmonary disease (COPD) includes both obstructive and inflammatory components. OBJECTIVE: The aim of this study was to confirm the findings of a previous study that compared the efficacy of a combination of 2 short-acting bronchodilators with the use of an inhaled corticosteroid and a long-acting beta-agonist in the treatment of COPD... CONCLUSION: In this 8-week study, subjects with moderate to severe COPD experienced greater improvements in lung function and symptom measures with FSC than with IB/ALB.
Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. [1997.08]
BACKGROUND: Routine addition of ipratropium bromide to beta-agonist therapy in acute asthma is of uncertain benefit. OBJECTIVE: This study was carried out to evaluate: (1) whether nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent) confers additional bronchodilation over nebulized salbutamol (2.5 mg) alone in patients with acute asthma and (2) whether adjustment for prognostic indicators of outcome influences any benefit seen with ipratropium... CONCLUSION: A single dose of nebulized Combivent confers additional bronchodilation over salbutamol alone (p < 0.05) in acute asthma. Patients who exhibited most benefit from the addition of ipratropium were those who had consumed the least inhaled beta-agonist before presentation, not those with the most severe asthma.
The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. [1997.02]
The role of ipratropium bromide as adjunct therapy to beta-agonists in acute asthma is uncertain. We therefore decided to compare the use of 3 mg of salbutamol sulfate alone vs 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide in patients with acute asthma.In conclusion, this large multicenter study failed to show a significantly better response to a combination of salbutamol and ipratropium bromide vs salbutamol alone.
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. [2009.09.06]
BACKGROUND: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. This trial compared tiotropium, once daily, as a potential alternative to patients already taking the ipratropium/albuterol combination... CONCLUSION: Patients previously maintained on the ipratropium/albuterol combination taken four times daily can be switched to tiotropium once daily with the reasonable expectation of at least equivalent bronchodilation during daytime hours and superior bronchodilation during early morning hours.
Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI *. [2009.03]
ABSTRACT Objective: Bronchodilator maintenance treatment improves pulmonary function and health-related quality of life in COPD patients. Pulmonary function and patient preference/satisfaction were compared before and after treatment with a short-acting ipratropium/albuterol combination and long-acting nebulized formoterol...
Clinical Trials Related to Combivent (Ipratropium / Albuterol)
Respimat Combivent Trial in COPD [Completed]
The primary objective of this study is to compare the effect of ipratropium
bromide/salbutamol inhalation spray combination administered by the Respimat? inhaler (20
mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat? inhaler (20
mcg), and COMBIVENT? MDI administered q. i.d on FEV1 at intervals over a treatment period of
12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat? to
COMBIVENT? MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat? to Atrovent
Respimat? monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent
Respimat? to Atrovent Respimat? monotherapy in FEV1 AUC from 4 to 6 hours will b e analyzed.
In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of
therapy will be characterized in a subgroup of patients.
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma [Recruiting]
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI
with albuterol HFA MDI, the current standard reliever medication in asthma. In the first
cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC
MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3)
COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at
the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will
be used for symptom relief as needed.
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma [Completed]
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent? Inhalation Aerosol in COPD Patients. [Completed]
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with
tiotro pium HandiHaler? 18 mcg daily compared to Combivent? MDI CFC Inhalation Aerosol 2
actuations qid in COPD patients currently prescribed Combivent? MDI.
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent? Inhalation Aerosol in COPD Patients. [Completed]
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with
tiotro pium HandiHaler? 18 mcg daily compared to Combivent? MDI CFC Inhalation Aerosol 2
actuations qid in COPD patients currently prescribed Combivent? MDI.
|
